Coliced
(Colistimethate Sodium 1M/2M/4.5M IU Inj.)
INDICATIONS
Used for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli (E. aerogenes, Escherichia coli, K. pneumoniae and P. aeruginosa).
ADMINISTRATION AND DOSAGE
IDSA and ATS 2016 guidelines - Management of Adults With Hospital-acquired Pneumonia (HAP) and Ventilator-associated Pneumonia (VAP)
| Recommendation | |
|---|---|
| Antibiotic Should Be Used to Treat Patients With HAP/VAP Due to Carbapenem-Resistant Pathogens | In patients with HAP/VAP caused by a carbapenem-resistant pathogen that is sensitive only to polymyxins, we recommended intravenous colistin (strong recommendation, moderate-quality evidence) |
Evaluate clinical/microbiological efficacy of the high-dose COL (Colistin) treatment under CVVH (continuous veno-venous hemofiltration) in patients with newly diagnosed MDR-GNB VAP (multidrug resistant gram-negative bacteria ventilator-associated pneumonia)- Observational cohort study
METHOD: Colistimethate sodium (CMS) was administered as a 9 million international units (MIU) of loading dose followed by 3 * 4.5 MIU daily. CVVH was performed over a highly adsorptive membrane. Clinical and microbiological efficacies were assessed at the end of therapy. In survivors, serum creatinine level was evaluated before and at the end of therapy.
| Isolated Pathogens | |
|---|---|
| Pseudomonas aeruginosa | 7 |
| Klebsiella pneumoniae | 5 |
| Enterobacteriaceae | 2 |
| RESULTS | Number of patients included in study-14 (8 male patients, aged 57 plus/minus 14 years) |
|---|---|
| Favorable clinical response | 9 patients (64%) |
| Full and presumed microbiological eradication | 12 patients (86%) |
| Diagnosed with Stage 1 acute kidney injury | 2 patients |
CONCLUSION:
In patients with MDR-GNB VAP, CVVH may represent an interesting option to enable effective high-dose COL treatment.